Physician profile
Amanda A Borham
NPI 1013184001
$7,467.76
in general payments reported to CMS, 2019-2025
25 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.39 · 2021: $483 · 2022: $831 · 2023: $1,726 · 2024: $2,553 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,887 · Education: $203 · Travel and Lodging: $19.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,887.02 |
| Education | $203.45 |
| Travel and Lodging | $19.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,504.67 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $1,798.71 | 2021-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $683.14 | 2021-2025 | Tavneos, Enbrel, Otezla |
| Glaxosmithkline, LLC. | $605.26 | 2021-2025 | Benlysta |
| Janssen Scientific Affairs, LLC | $408.91 | 2021-2024 | Tremfya |
| Ucb, INC. | $244.94 | 2020-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $200.39 | 2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $175.98 | 2024-2025 | Saphnelo |
| Pfizer INC. | $165.91 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $145.55 | 2022-2025 | Acthar |
| Bioventus LLC | $83.89 | 2024-2025 | Durolane, Gelsyn-3 |
| Radius Health, INC. | $64.03 | 2024-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $58.02 | 2024-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $45.06 | 2020-2025 | Orencia |
| Sandoz INC. | $35.77 | 2023-2025 | Jubbonti, Hyrimoz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $35.34 | 2024-2025 | Hymovis, Triluron, Hyalgan |
| Merz North America, INC. | $35.24 | 2023 | Xeomin |
| Novartis Pharmaceuticals Corporation | $34.68 | 2023-2024 | |
| Depuy Synthes Sales INC. | $28.93 | 2022-2023 | Monovisc |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.31 | 2022-2024 | Cyltezo |
| Almatica Pharma LLC | $19.62 | 2025 | Teriparatide |
| Organon LLC | $18.70 | 2025 | Nexplanon |
| Genzyme Corporation | $18.65 | 2024 | |
| Si-Bone, INC. | $14.81 | 2021 | |
| Sobi, INC | $13.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Borham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.